Literature DB >> 8298528

Prevalence and magnitude of osteopenia in patients with prolactinoma.

M J Kayath1, A M Lengyel, J G Vieira.   

Abstract

1. The association between hypogonadism and osteoporosis has been reported. We conducted a study to establish the prevalence and magnitude of osteopenia in patients with prolactinoma and the relationship of bone loss with the duration of hypogonadism. 2. We measured the bone mineral density (BMD) of spine and femur (a site that has not been analyzed earlier) in 35 patients with prolactinoma using a dual-energy X-ray absorptiometer. The patients were classified as normal BMD and low BMD (osteopenics). 3. Seventeen patients (48%) showed osteopenia. The mean bone loss in the different regions was: spine, 13%; femoral neck, 15%; trochanter, 11%; Ward's, 22%. This difference was only significant when the spine and Ward's region were compared. The duration of hypogonadism was significantly greater in the low-BMD group (11.3 vs 4.9 years) when compared to the normal BMD group. There was a positive relationship between the duration of hypogonadism and magnitude of bone loss in both spine and femur (P = 0.04; r = 0.6). 4. A high prevalence of osteopenia in both spine and femur was found in patients with prolactinoma, and was highly associated with the duration of hypogonadism. Early treatment of this condition seems important to prevent bone loss.

Entities:  

Mesh:

Year:  1993        PMID: 8298528

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  5 in total

1.  Prevalence of osteopenia in men with prolactinoma.

Authors:  E C O Naliato; M L F Farias; G R Braucks; F S R Costa; D Zylberberg; A H D Violante
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 2.  The effects of hyperprolactinemia on bone and fat.

Authors:  Amal Shibli-Rahhal; Janet Schlechte
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

3.  Bone density in women with prolactinoma treated with dopamine agonists.

Authors:  Erika Cesar de Oliveira Naliato; Alice Helena Dutra Violante; Dayse Caldas; Maria Lucia Fleiuss Farias; Isabela Bussade; Adilson Lamounier Filho; Christiane Rezende Loureiro; Rosita Fontes; Yolanda Schrank; Thaissa Loures; Annamaria Colao
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 4.  Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications.

Authors:  Matthieu P K Crews; Oliver D Howes
Journal:  Hum Psychopharmacol       Date:  2012-01-09       Impact factor: 1.672

Review 5.  Potential mechanisms linking psychological stress to bone health.

Authors:  Jia-Sheng Ng; Kok-Yong Chin
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.